Synergy between small-molecule inhibitors of EGFR and AURKA was first identified in a synthetic lethality screen performed in EGFR-overexpressing head and neck squamous cell carcinomas and colorectal cancers (27). Here, EGFR is linked to head and neck squamous cell carcinoma.